Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171257 · ClinicalTrials.gov registry record
Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 197
- Enrollment target
NCT05171257: Completed study, sponsored by Methodist Health System.
NCT05171257 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 197 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05171257 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 197 participants
- Enrollment target
Study Summary
Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor. For example, the use of non-antipseudomonal agents can increase risk for any P. aeruginosa strain; however, the use of an agent with antipseudomonal activity would select for resistance to that particular antimicrobial agent or class. Demonstrated that each additional day of exposure to any antipseudomonal beta-lactam is associated with an increased risk of new resistance development. The study seeks to determine whether the choice of empiric therapy (i.e., the same agent versus a different agent from prior antibiotic exposure) has any effect on the likelihood of in vitro activity against GN pathogens (GNPs) in a subsequent infection.
Primary Outcome
Rates of resistance in patients receiving empiric therapy with the same IV antibiotics from prior (repeat group) compared to rates of resistance in patients receiving differing IV antibiotics from prior (change group)
Interventions
- DRUG IV antibiotic treatment from prior
- DRUG differing IV antibiotic treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2025-07-14 |
What the finished NCT05171257 record still lists
NCT05171257 is an observational study that tracks outcomes without assigning an intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which IV antibiotic treatment from prior is the first listed.
NCT05171257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05171257 about?
NCT05171257 is a clinical study titled "Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit". Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor. For example, the use of non-antipseudomonal agents can increase risk for any P. aeru...
What is the current status of trial NCT05171257?
This trial is currently completed. The enrollment target is 197 participants. The study started on 2021-10-19. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT05171257?
The interventions under investigation include: IV antibiotic treatment from prior (DRUG), differing IV antibiotic treatment (DRUG).
Who is sponsoring clinical trial NCT05171257?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI